PET scan
$3,000–$7,000 per scan
Not scalable
Parkinson's and Alzheimer's begin in the brain a decade or more before the first clinical symptom. The body emits a disease-related odor signature long before then — and we read it, using trained animal olfactory systems today and a neuromorphic sensor in development. Non-invasive, scalable, mail-in.
By the time symptoms appear, the disease has already taken hold. Most of healthcare's cost arrives after diagnosis — because detection is late.
Disease-process estimate from Lewy-body / Braak staging and prodromal cohort studies (Postuma et al., Brain 2019; Berg et al., Mov Disord 2015).
$3,000–$7,000 per scan
Not scalable
Invasive procedure
Low patient acceptance
Expensive imaging
Detects late-stage damage
Free observation
10–15 years too late
We do not test the person's own sense of smell. We detect a chemical signature the body emits — reading it with animal olfactory systems today, and a neuromorphic sensor in development, to flag potential Parkinson's (and, later, Alzheimer's) years before symptoms.
Published field evidence that the emitted signature exists and is detectable: Rooney 2025 (canine PD detection); Trivedi 2019 (VOC signature, ACS Central Science); Walton-Doyle 2025 (prodromal, npj Parkinson's Disease). See the Science page.
Mail-in human samples, read by trained multi-species olfactory detectors — dogs, rats, and bees. Mexico-based operations, recurring revenue. Customers are pharma and CROs, clinics and hospitals, and individuals seeking early risk information — never animals or their trainers.
Bio-inspired silicon. Alzheimer's enters here as a second indication — a VOC-discovery program on the same platform. Pharma research devices, clinical sensing, per-screen licensing — the long-term moat.
of Japan's population is already aged 65+ — the highest share of any major economy, projected to reach 34.8% by 2040.
spent annually on 人間ドック (ningen dock) preventive screening — a ~$3B market with 3.7M+ voluntary participants. An entrenched behavior, not one we must create.
Sources: Japan Ministry of Internal Affairs & Communications, Sept 2025 (record 29.4% aged 65+); Japan IPSS (2040 projection). Japan Society of Ningen Dock — ~3.7M voluntary participants/year across 1,700+ certified facilities; ~¥471B (~$3B) annual market. Mandatory employer screening covers ~28M additional adults.
Most digital-health startups must teach consumers to want screening. We slot into a behavior they already have.
Co-Founder · CEO · Digital Health
Researcher at Universidad Veracruzana. Member of Mexico's National System of Researchers. Expertise in digital health platforms, decision-support systems, and software for neurological disorders. Published in MDPI Healthcare, Sustainability, and AppliedMath.
Co-Founder · Animal Behavior & Detection
PhD in Neuroethology, Universidad Veracruzana. Faculty in Veterinary Medicine. Member of Mexico's National System of Researchers (Level I). Peer-reviewed publications in animal cognition, olfactory training, and behavioral protocols. Leads Mexico operations.
Co-Founder
Staff Scientist at OIST (Neural Computation Unit, Prof. Doya). Computational neuroscience and AI for neurodegenerative disease modeling. Director of Exponential Japan KK. 15+ years building Japan's innovation ecosystem. AI XPRIZE Ambassador for Japan.
Current applications · OIST Innovation Accelerator 2027–2028 →